

28. (Cancelled) The package as claimed in claim 27 wherein the doses are in tablet form.
29. (Currently Amended) ~~The method as claimed in claim 14~~ The use as in claim 19 wherein the daily doses in the relatively dominant estrogenic activity phase comprise about 1 mg per day of 17 $\beta$ -estradiol, and in the relatively dominant progestogenic activity phase comprise about 1 mg per day of 17 $\beta$ -estradiol and about 90  $\mu$ g per day of norgestimate.
30. (Original) The method as claimed in claim 29 wherein the doses are in oral form.
31. (Original) The method as claimed in claim 30 wherein the doses are in tablet form.
32. (Original) The use as claimed in claim 20 in which the daily doses in the relatively dominant estrogenic activity phase comprises about 1 mg per day of 17 $\beta$ -estradiol, and in the relatively dominant progestogenic activity phase comprises about 1 mg per day of 17 $\beta$ -estradiol and about 90  $\mu$ g per day of norgestimate.
33. (Original) The use as claimed in claim 32 wherein the doses are in oral form.
34. (Original) The use as claimed in claim 33 wherein the doses are in tablet form.

#### **REMARKS**

Claim 29 has been amended. No new matter has been added by virtue of the within amendment. For example, Applicants present this Supplemental Amendment merely to correct dependency of Claim 29.


It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

If the undersigned can be of any assistance in advancing the prosecution of this case, the Examiner is invited to telephone him at the numbers given below.

Respectfully submitted,

Date: September 15, 2004

By:



Gregory B. Butler, Ph.D., Esq.

Reg. No.: 34,558

EDWARDS & ANGELL, LLP

P.O. Box 55874

Boston, MA 02205

Tel: 617-439-4444

Fax: 617-439-4170

Customer No.: 21874